NO975129L - <alfa>- substituerte pyrimidin-thioalkyl og alkyleterforbindelser som inhibitorer av viral revers transkriptase - Google Patents
<alfa>- substituerte pyrimidin-thioalkyl og alkyleterforbindelser som inhibitorer av viral revers transkriptaseInfo
- Publication number
- NO975129L NO975129L NO975129A NO975129A NO975129L NO 975129 L NO975129 L NO 975129L NO 975129 A NO975129 A NO 975129A NO 975129 A NO975129 A NO 975129A NO 975129 L NO975129 L NO 975129L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- reverse transcriptase
- alfa
- thioalkyl
- alkyl ether
- Prior art date
Links
- 102100034343 Integrase Human genes 0.000 title abstract 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 title abstract 2
- -1 alkyl ether compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43670895A | 1995-05-08 | 1995-05-08 | |
| PCT/US1996/006119 WO1996035678A1 (en) | 1995-05-08 | 1996-05-03 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975129D0 NO975129D0 (no) | 1997-11-07 |
| NO975129L true NO975129L (no) | 1998-01-07 |
| NO310287B1 NO310287B1 (no) | 2001-06-18 |
Family
ID=23733510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975129A NO310287B1 (no) | 1995-05-08 | 1997-11-07 | <alfa>-substituerte pyrimidintioalkyl- og alkyleterforbindelser og farmasöytisk preparat inneholdende dissesom inhibitorer av viral reverstranskriptase |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6043248A (no) |
| EP (2) | EP1449835A3 (no) |
| JP (1) | JPH11507017A (no) |
| KR (1) | KR100445498B1 (no) |
| CN (2) | CN1535958A (no) |
| AT (1) | ATE275550T1 (no) |
| AU (1) | AU712404B2 (no) |
| BR (1) | BR9608265A (no) |
| CA (1) | CA2216099C (no) |
| CZ (1) | CZ293135B6 (no) |
| DE (1) | DE69633332T2 (no) |
| ES (1) | ES2227586T3 (no) |
| GE (1) | GEP20002297B (no) |
| HU (1) | HUP9801995A3 (no) |
| IL (1) | IL118075A0 (no) |
| MX (1) | MX9708582A (no) |
| NO (1) | NO310287B1 (no) |
| NZ (1) | NZ307089A (no) |
| PL (1) | PL323240A1 (no) |
| PT (1) | PT824524E (no) |
| RU (1) | RU2167155C2 (no) |
| SK (1) | SK150297A3 (no) |
| TW (1) | TW450962B (no) |
| UA (1) | UA56992C2 (no) |
| WO (1) | WO1996035678A1 (no) |
| ZA (1) | ZA963281B (no) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999019304A2 (en) * | 1997-09-25 | 1999-04-22 | Pharmacia & Upjohn Company | Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors |
| US6111111A (en) | 1997-10-23 | 2000-08-29 | Kuraray Co., Ltd. | Intermediates for producing pyridine derivatives |
| TR200100773T2 (tr) | 1998-09-17 | 2001-07-23 | Bristol-Myers Squibb Company | Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi |
| US7358254B2 (en) | 2001-07-13 | 2008-04-15 | Bristol-Myers Squibb Company | Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| EP1194152A4 (en) | 1999-06-30 | 2002-11-06 | Merck & Co Inc | Links to SRC kinase inhibition |
| AU6605200A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US7138404B2 (en) * | 2001-05-23 | 2006-11-21 | Hoffmann-La Roche Inc. | 4-aminopyrimidine derivatives |
| CN101068550B (zh) * | 2004-12-03 | 2011-03-30 | 默沙东公司 | 含有释放速度控制组分的羧酰胺人类免疫缺陷整合酶抑制剂药物制剂 |
| PT1858861E (pt) * | 2005-03-04 | 2010-09-16 | Tibotec Pharm Ltd | 2-(4-cianofenil)-6-hidroxilaminopirimidinas inibidoras do hiv |
| US7923056B2 (en) | 2007-06-01 | 2011-04-12 | Illinois Tool Works Inc. | Method and apparatus for dispensing material on a substrate |
| AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
| CN101638391B (zh) * | 2009-08-21 | 2011-04-27 | 山东大学 | 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用 |
| WO2011103559A1 (en) | 2010-02-22 | 2011-08-25 | Nektar Therapeutics | Oligomer modified diaromatic substituted compounds |
| ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
| MX2012015097A (es) * | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| WO2012170765A2 (en) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| KR101360587B1 (ko) * | 2012-11-01 | 2014-03-10 | 현대자동차주식회사 | 스마트 도어 언록 시스템 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| RS63653B1 (sr) | 2015-07-22 | 2022-11-30 | Enanta Pharm Inc | Benzodiazepinski derivati kao inhibitori rsv |
| GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
| MX2022003984A (es) * | 2019-10-04 | 2022-07-27 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| EP4093198A4 (en) * | 2020-01-20 | 2024-01-24 | Agrematch Ltd. | Compositions for crop protection |
| KR20240056718A (ko) | 2021-08-10 | 2024-04-30 | 아이에프엠 듀, 인크. | Sting 활성과 연합된 상태를 치료하기 위한 화합물 및 조성물 |
| CN114057707A (zh) * | 2021-11-24 | 2022-02-18 | 上海应用技术大学 | 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法 |
| JP2025504415A (ja) * | 2022-01-12 | 2025-02-12 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2295560A (en) * | 1941-06-18 | 1942-09-15 | Gen Electric | Pyrimidine derivatives |
| GB744867A (en) * | 1952-10-29 | 1956-02-15 | American Cyanamid Co | Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof |
| US3940394A (en) * | 1972-03-31 | 1976-02-24 | Santilli Arthur A | 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides |
| US3940240A (en) * | 1974-07-11 | 1976-02-24 | Ina Seito Co., Ltd. | Baking method and kiln for tile |
| DE3369514D1 (en) * | 1983-05-05 | 1987-03-05 | Heumann Ludwig & Co Gmbh | Pyrimidinethioalkyl pyridine derivatives, process for their preparation and medicines containing these compounds |
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| JPS62209062A (ja) * | 1986-03-10 | 1987-09-14 | Yamanouchi Pharmaceut Co Ltd | ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物 |
| JPH07107056B2 (ja) * | 1987-01-30 | 1995-11-15 | 日清製粉株式会社 | ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤 |
| WO1989011279A1 (en) * | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
| HU203736B (en) * | 1989-04-06 | 1991-09-30 | Gyogyszerkutato Intezet | Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them |
| HK1002235A1 (en) * | 1989-12-28 | 1998-08-07 | Pharmacia & Upjohn Company | Diaromatic substituted anti-aids compounds |
| US5668136A (en) * | 1990-09-25 | 1997-09-16 | Eisai Co., Ltd. | Trisubstituted benzene derivatives, composition and methods of treatment |
| WO1993001181A1 (en) * | 1991-07-03 | 1993-01-21 | The Upjohn Company | Substituted indoles as anti-aids pharmaceuticals |
| GB2266716A (en) * | 1992-05-05 | 1993-11-10 | Merck & Co Inc | Inhibitors of HIV reverse transcriptase |
| JP3077046B2 (ja) * | 1992-08-31 | 2000-08-14 | 久光製薬株式会社 | 新規なキナゾリン誘導体 |
| WO1995007901A1 (en) * | 1993-09-17 | 1995-03-23 | The Upjohn Company | Substituted tetronic acids useful for treating hiv and other retroviruses |
| EP0728130A1 (en) * | 1993-11-12 | 1996-08-28 | PHARMACIA & UPJOHN COMPANY | Pyrimidine-thioalkyl and alkylether compounds |
| WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| US6162809A (en) * | 1994-07-10 | 2000-12-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridylthio compounds for controlling helicobacter bacteria |
-
1996
- 1996-03-05 UA UA97125800A patent/UA56992C2/uk unknown
- 1996-04-24 ZA ZA9603281A patent/ZA963281B/xx unknown
- 1996-04-29 IL IL11807596A patent/IL118075A0/xx unknown
- 1996-05-03 AT AT96913306T patent/ATE275550T1/de not_active IP Right Cessation
- 1996-05-03 RU RU97120116/04A patent/RU2167155C2/ru not_active IP Right Cessation
- 1996-05-03 DE DE69633332T patent/DE69633332T2/de not_active Expired - Fee Related
- 1996-05-03 EP EP04010159A patent/EP1449835A3/en not_active Withdrawn
- 1996-05-03 AU AU56353/96A patent/AU712404B2/en not_active Ceased
- 1996-05-03 BR BR9608265A patent/BR9608265A/pt not_active Application Discontinuation
- 1996-05-03 JP JP8534120A patent/JPH11507017A/ja not_active Withdrawn
- 1996-05-03 CN CNA200410032589XA patent/CN1535958A/zh active Pending
- 1996-05-03 PL PL96323240A patent/PL323240A1/xx unknown
- 1996-05-03 CA CA002216099A patent/CA2216099C/en not_active Expired - Fee Related
- 1996-05-03 MX MX9708582A patent/MX9708582A/es not_active IP Right Cessation
- 1996-05-03 HU HU9801995A patent/HUP9801995A3/hu unknown
- 1996-05-03 EP EP96913306A patent/EP0824524B1/en not_active Expired - Lifetime
- 1996-05-03 US US08/945,153 patent/US6043248A/en not_active Expired - Fee Related
- 1996-05-03 KR KR1019970707927A patent/KR100445498B1/ko not_active Expired - Fee Related
- 1996-05-03 ES ES96913306T patent/ES2227586T3/es not_active Expired - Lifetime
- 1996-05-03 WO PCT/US1996/006119 patent/WO1996035678A1/en not_active Ceased
- 1996-05-03 CZ CZ19973491A patent/CZ293135B6/cs not_active IP Right Cessation
- 1996-05-03 SK SK1502-97A patent/SK150297A3/sk unknown
- 1996-05-03 GE GEAP19964013A patent/GEP20002297B/en unknown
- 1996-05-03 PT PT96913306T patent/PT824524E/pt unknown
- 1996-05-03 NZ NZ307089A patent/NZ307089A/xx unknown
- 1996-05-03 CN CNB961937912A patent/CN1152022C/zh not_active Expired - Fee Related
- 1996-05-07 TW TW085105432A patent/TW450962B/zh not_active IP Right Cessation
-
1997
- 1997-11-07 NO NO19975129A patent/NO310287B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO975129L (no) | <alfa>- substituerte pyrimidin-thioalkyl og alkyleterforbindelser som inhibitorer av viral revers transkriptase | |
| MY146669A (en) | Pyrazole derivatives for treating hiv | |
| TR200003011T2 (tr) | Yeni dihidropirimidinler. | |
| DE69818094D1 (de) | Antivirale verbindungen | |
| ATE238998T1 (de) | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore | |
| DE60036862D1 (de) | Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid-analoge | |
| WO1999019304A3 (en) | Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors | |
| DE69928779D1 (de) | Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion | |
| ES2123156T3 (es) | Compuestos y procedimientos de inhibicion de hiv y virus semejantes. | |
| ATE319680T1 (de) | Substituierte 2-benzylamino-2-phenyl- acetamidverbindungen | |
| TR200001288T2 (tr) | Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler. | |
| MXPA03001081A (es) | Medicamento anti-inflamatorio. | |
| NO985679D0 (no) | Dihydrobenzopyran og beslektede forbindelser nyttige som anti-inflammasjonsmidler | |
| DK0604186T3 (da) | HIV-proteaseinhibitorer, som er egnede til behandling af AIDS | |
| YU6396A (sh) | Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija | |
| ES2116591T3 (es) | Cicloalquilhidroxiureas y su uso como inhibidores de la lipoxigenasa. | |
| NO951608D0 (no) | Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon | |
| SE9402241L (sv) | Inhibitor | |
| AU6835096A (en) | A new family of compounds having anti-inflammatory and anti-viral activity and compositions of these, alone and in combination with reverse transcriptase inhibitors, for inhibiting, preventing or eliminating viral replication and methods of using same | |
| DK0644873T3 (da) | Forgrenede aminooxy-amino-alkan-derivater som ornithindecarboxylase-inhibitorer | |
| ATE327235T1 (de) | 1,2,5,10-tetrahydropyridazino 4,5-böchinolin-1, 0-dione und ihre anwendung in der behandlung von schmerzen |